Ryon P. Graf
About
Ryon P. Graf is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Ryon P. Graf has authored 111 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 64 papers in Oncology and 63 papers in Cancer Research. Recurrent topics in Ryon P. Graf's work include Cancer Genomics and Diagnostics (57 papers), Prostate Cancer Treatment and Research (47 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Ryon P. Graf is often cited by papers focused on Cancer Genomics and Diagnostics (57 papers), Prostate Cancer Treatment and Research (47 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Ryon P. Graf collaborates with scholars based in United States, United Kingdom and Spain. Ryon P. Graf's co-authors include Ryan Dittamore, Howard I. Scher, Nicole A. Schreiber, David Lu, Jessica Louw, Glenn Heller, Martin Fleisher, Brigit McLaughlin, Dena Marrinucci and Adam Jendrisak and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
In The Last Decade
Ryon P. Graf
99 papers receiving 2.4k citations
Hit Papers
Peers
Ryon P. Graf
Ryan Dittamore United States
Aseem Anand United States
Magalie Hilton Switzerland
Peter Kabos United States
Ricardo H. Álvarez United States
Lisha G. Brown United States
Benjamin Ory France
Kazuhiko Shien Japan
Adam G. Sowalsky United States
Marta Guix Spain
Citations per year, relative to Ryon P. Graf Ryon P. Graf (= 1×)
peers
Ryan Dittamore
Countries citing papers authored by Ryon P. Graf
Since
Specialization
Citations
This map shows the geographic impact of Ryon P. Graf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryon P. Graf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryon P. Graf more than expected).
Fields of papers citing papers by Ryon P. Graf
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ryon P. Graf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryon P. Graf. The network helps show where Ryon P. Graf may publish in the future.
Co-authorship network of co-authors of Ryon P. Graf
This figure shows the co-authorship network connecting the top 25 collaborators of Ryon P. Graf. A scholar is included among the top collaborators of Ryon P. Graf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryon P. Graf. Ryon P. Graf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Graf, Ryon P., Nicolas Sayegh, Gerald Li, et al.. (2025). Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer. Clinical Cancer Research. 31(19). 4101–4109.
2.
Slomovitz, Brian M., Natalie Danziger, Júlia C.F. Quintanilha, et al.. (2025). Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer. International Journal of Gynecological Cancer. 35(10). 102107–102107.
3.
Swami, Umang, Yeonjung Jo, Nicolas Sayegh, et al.. (2025). Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US.. Journal of Clinical Oncology. 43(5_suppl). 95–95.
4.
Richardson, Debra L., Júlia C.F. Quintanilha, Natalie Danziger, et al.. (2024). Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice. Clinical Cancer Research. 30(20). 4644–4653.
5.
Bhave, Manali, Júlia C.F. Quintanilha, Ryon P. Graf, et al.. (2024). Abstract PO2-16-05: ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real-world practice. Cancer Research. 84(9_Supplement). PO2–16.
6.
Gupta, Shilpa, et al.. (2024). Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology. 8(8). e2300562–e2300562.
7.
Bhave, Manali, Júlia C.F. Quintanilha, Hanna Tukachinsky, et al.. (2024). Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Research and Treatment. 207(3). 599–609.
8.
Sweeney, Christopher J., Chang Xu, Jie He, et al.. (2024). Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 30(18). 4115–4122.
9.
Quintanilha, Júlia C.F., Ryon P. Graf, Gerald Li, et al.. (2023). Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. JCO Precision Oncology. 7(7). 26–27.
10.
Sweeney, Christopher, Ryon P. Graf, David Fabrizio, et al.. (2023). Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.. Journal of Clinical Oncology. 41(6_suppl). LBA249–LBA249.
11.
Ellis, Haley, Samuel J. Klempner, Parvathi A. Myer, et al.. (2023). Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 41(4_suppl). 46–46.
12.
Huang, Richard S.P., David P. Carbone, Gerald Li, et al.. (2023). Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. Journal for ImmunoTherapy of Cancer. 11(1). e005801–e005801.
13.
Zhang, Liangliang, Ryon P. Graf, Hanna Tukachinsky, et al.. (2023). The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer. Clinical Genitourinary Cancer. 22(1). e163–e169.e1.
14.
Graf, Ryon P., Virginia Fisher, Richard S.P. Huang, et al.. (2022). Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma. JCO Precision Oncology. 6(6). e2200121–e2200121.
15.
Graf, Ryon P., Virginia Fisher, James Creeden, et al.. (2022). Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer. Cancer Research Communications. 2(9). 1037–1048.
16.
Swami, Umang, Ryon P. Graf, Roberto Nussenzveig, et al.. (2022). SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research. 28(22). 4917–4925.
17.
Malihi, Paymaneh D., Ryon P. Graf, Ángel Rodríguez, et al.. (2020). Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clinical Cancer Research. 26(15). 4143–4153.
18.
Boffa, Daniel J., Ryon P. Graf, Michelle C. Salazar, et al.. (2017). Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiology Biomarkers & Prevention. 26(7). 1139–1145.
19.
Scher, Howard I., Ryon P. Graf, Nicole A. Schreiber, et al.. (2017). Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer Research. 77(20). 5687–5698.
20.
Beltran, Himisha, Adam Jendrisak, Mark Landers, et al.. (2015). The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research. 22(6). 1510–1519.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ryan Dittamore Breakdown of academic impact, for papers by Aseem Anand Breakdown of academic impact, for papers by Magalie Hilton Breakdown of academic impact, for papers by Peter Kabos Breakdown of academic impact, for papers by Ricardo H. Álvarez Breakdown of academic impact, for papers by Lisha G. Brown Breakdown of academic impact, for papers by Benjamin Ory Breakdown of academic impact, for papers by Kazuhiko Shien Breakdown of academic impact, for papers by Adam G. Sowalsky Breakdown of academic impact, for papers by Marta Guix